Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine MarketBusiness Wire • 02/12/26
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by AlkermesGlobeNewsWire • 01/12/26
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic HypersomniaGlobeNewsWire • 12/18/25
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General MeetingGlobeNewsWire • 12/03/25
Announcement relating to convening of Scheme Meeting and Extraordinary General MeetingGlobeNewsWire • 12/01/25
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”GlobeNewsWire • 11/17/25
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel DealBenzinga • 11/14/25
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/04/25
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)PRNewsWire • 10/22/25